TY - JOUR
T1 - Characterizing perfusion defects in metastatic lymph nodes at an early stage using high-frequency ultrasound and micro-CT imaging
AU - Yamaki, Teppei
AU - Sukhbaatar, Ariunbuyan
AU - Mishra, Radhika
AU - Kikuchi, Ryoichi
AU - Sakamoto, Maya
AU - Mori, Shiro
AU - Kodama, Tetsuya
N1 - Funding Information:
The study was supported by KAKENHI grants from the Japan Society for the Promotion of Science (20K20161 to Ariunbuyan Sukhbaatar; 18H03544 to Maya Sakamoto; and 19K22941, 20H00655, and 21K18319 to Tetsuya Kodama).
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature B.V.
PY - 2021/12
Y1 - 2021/12
N2 - A perfusion defect in a metastatic lymph node (LN) can be visualized as a localized area of low contrast on contrast-enhanced CT, MRI or ultrasound images. Hypotheses for perfusion defects include abnormal hemodynamics in neovascular vessels or a decrease in blood flow in pre-existing blood vessels in the parenchyma due to compression by LN tumor growth. However, the mechanisms underlying perfusion defects in LNs during the early stage of LN metastasis have not been investigated. We show that tumor mass formation with very few microvessels was associated with a perfusion defect in a non-enlarged LN at the early stage of LN metastasis in a LN adenopathy mouse (LN size circa 10 mm). We found in a mouse model of LN metastasis, induced using non-keratinizing tumor cells, that during the formation of the perfusion defect in a non-enlarged LN, the number of blood vessels ≤ 50 μm in diameter decreased, while those of > 50 μm in diameter increased. The methods used were contrast-enhanced high-frequency ultrasound and contrast-enhanced micro-CT imaging systems, with a maximum spatial resolution of > 30 μm. Furthermore, we found no tumor angiogenesis or oxygen partial pressure (pO2) changes in the metastatic LN. Our results demonstrate that the perfusion defect appears to be a specific form of tumorigenesis in the LN, which is a vascular-rich organ. We anticipate that a perfusion defect on ultrasound, CT or MRI images will be used as an indicator of a non-enlarged metastatic LN at an early stage.
AB - A perfusion defect in a metastatic lymph node (LN) can be visualized as a localized area of low contrast on contrast-enhanced CT, MRI or ultrasound images. Hypotheses for perfusion defects include abnormal hemodynamics in neovascular vessels or a decrease in blood flow in pre-existing blood vessels in the parenchyma due to compression by LN tumor growth. However, the mechanisms underlying perfusion defects in LNs during the early stage of LN metastasis have not been investigated. We show that tumor mass formation with very few microvessels was associated with a perfusion defect in a non-enlarged LN at the early stage of LN metastasis in a LN adenopathy mouse (LN size circa 10 mm). We found in a mouse model of LN metastasis, induced using non-keratinizing tumor cells, that during the formation of the perfusion defect in a non-enlarged LN, the number of blood vessels ≤ 50 μm in diameter decreased, while those of > 50 μm in diameter increased. The methods used were contrast-enhanced high-frequency ultrasound and contrast-enhanced micro-CT imaging systems, with a maximum spatial resolution of > 30 μm. Furthermore, we found no tumor angiogenesis or oxygen partial pressure (pO2) changes in the metastatic LN. Our results demonstrate that the perfusion defect appears to be a specific form of tumorigenesis in the LN, which is a vascular-rich organ. We anticipate that a perfusion defect on ultrasound, CT or MRI images will be used as an indicator of a non-enlarged metastatic LN at an early stage.
KW - CT
KW - Focal perfusion defect
KW - Lymph node metastasis
KW - Mouse model
KW - Non-enlarged lymph node
KW - Ultrasound
UR - http://www.scopus.com/inward/record.url?scp=85117119953&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117119953&partnerID=8YFLogxK
U2 - 10.1007/s10585-021-10127-6
DO - 10.1007/s10585-021-10127-6
M3 - Article
C2 - 34654990
AN - SCOPUS:85117119953
SN - 0262-0898
VL - 38
SP - 539
EP - 549
JO - Clinical and Experimental Metastasis
JF - Clinical and Experimental Metastasis
IS - 6
ER -